

Alison O'Mahony

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1630365/publications.pdf>

Version: 2024-02-01

9
papers

1,115
citations

1163117

8
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

2340
citing authors

#	ARTICLE	IF	CITATIONS
1	Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. <i>Nature Chemical Biology</i> , 2014, 10, 305-312.	8.0	296
2	CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 10768-10773.	7.1	200
3	Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy. <i>Cancer Research</i> , 2015, 75, 5106-5119.	0.9	193
4	A selective inhibitor reveals PI3K \hat{I} ³ dependence of TH17 cell differentiation. <i>Nature Chemical Biology</i> , 2012, 8, 576-582.	8.0	136
5	RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 341, 90-103.	2.5	128
6	Identification of a Chemical Probe for Family VIII Bromodomains through Optimization of a Fragment Hit. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4800-4811.	6.4	79
7	Regulation of IL-17A Production Is Distinct from IL-17F in a Primary Human Cell Co-culture Model of T Cell-Mediated B Cell Activation. <i>PLoS ONE</i> , 2013, 8, e58966.	2.5	39
8	Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures. <i>PLoS ONE</i> , 2019, 14, e0222944.	2.5	35
9	Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate. <i>Journal of Translational Medicine</i> , 2018, 16, 156.	4.4	6